Novavax Q3 EPS $(1.26) Beats $(1.83) Estimate, Sales $186.99M Beat $158.54M Estimate
Portfolio Pulse from Benzinga Newsdesk
Novavax reported Q3 earnings per share of $(1.26), beating the analyst consensus estimate of $(1.83) by 31.15%. This is a 41.4% increase over losses from the same period last year. The company also reported quarterly sales of $186.99 million, beating the analyst consensus estimate of $158.54 million by 17.94%. However, this is a 74.55% decrease over sales from the same period last year.
November 09, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Novavax's Q3 earnings beat analyst estimates, but sales are down significantly YoY. This mixed result could lead to uncertain short-term price movements.
Novavax's better-than-expected Q3 earnings could be a positive signal to investors, potentially driving the stock price up. However, the significant YoY decrease in sales could be a concern, potentially driving the stock price down. These opposing factors make the short-term impact on the stock uncertain.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100